Molecular neurodegeneration: basic biology and disease pathways by Robert Vassar & Hui Zheng
Vassar and Zheng Molecular Neurodegeneration 2014, 9:34
http://www.molecularneurodegeneration.com/content/9/1/34EDITORIAL Open AccessMolecular neurodegeneration: basic biology and
disease pathways
Robert Vassar1* and Hui Zheng2Abstract
The field of neurodegeneration research has been advancing rapidly over the past few years, and has provided
intriguing new insights into the normal physiological functions and pathogenic roles of a wide range of molecules
associated with several devastating neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease,
amyotrophic lateral sclerosis, frontotemporal dementia, Huntington’s disease, and Down syndrome. Recent
developments have also facilitated initial efforts to translate preclinical discoveries toward novel therapeutic
approaches and clinical trials in humans. These recent developments are reviewed in the current Review Series on
“Molecular Neurodegeneration: Basic Biology and Disease Pathways” in a number of state-of-the-art manuscripts that
cover themes presented at the Third International Conference on Molecular Neurodegeneration: “Basic biology and
disease pathways” held in Cannes, France, September, 2013.Text
In September 2013, the Third International Conference
on Molecular Neurodegeneration: “Basic biology and
disease pathways” was held in Cannes, France. The
three-day conference brought together scientists from
around the world to present and discuss the results of
their most recent research on the normal physiological
functions and pathological mechanisms of molecular
pathways that are relevant to neurodegenerative diseases
(Figure 1). The current thematic review series in the
journal, entitled “Molecular Neurodegeneration: Basic
Biology and Disease Pathways”, is intended to represent
not only the scientific findings presented during the
conference, but to also reflect the state-of-the-art in a
given field. The review series will consist of a “rolling
submission” format in which manuscripts by presenters
at the conference will appear at regular intervals in the
journal.
The conference covered a wide array of topics con-
cerning neurodegeneration at the genetic, molecular,
cellular, physiological, behavioral, and systems levels,
and with a translational perspective of moving dis-
coveries from preclinical models into human clinical* Correspondence: r-vassar@northwestern.edu
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generation research:
 The genetics of AD and other neurodegenerative
diseases
 The structure and normal physiological functions of
molecules involved in neurodegeneration
 Novel molecular mechanisms of AD, PD, ALS, FTD,
DS, and HD
 Mechanisms of neurotoxicity in PD, AD and other
tauopathies
 Novel therapeutic approaches for neurodegenerative
diseases
Molecular mechanisms of neurodegeneration were dom-
inant themes of the conference. Some highlights included
novel insights into AD pathogenesis provided by genetic
analyses revealing new AD risk factor genes like CD33 and
TREM2 involved in innate immunity [1-4]. Deeper know-
ledge of the structures and normal physiological functions
of APP and the α-, β- and γ-secretase enzymes that process
APP is assisting the development of disease-modifying AD
therapies that target the neurotoxic Aβ peptide [5-9]. Intri-
guing studies have revealed new molecules involved in
neurodegeneration, like C9ORF72 in ALS and FTD, and
begin to shed light on their pathogenic roles [10-12]. New
insights into the prion-like spread of Aβ and tau patholo-
gies in AD and α-synuclein in PD have also been madentral Ltd. This is an Open Access article distributed under the terms of the
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Figure 1 The Third International Conference on Molecular Neurodegeneration: “Basic biology and disease pathways” - Cannes, France.
The Conference was attended by 179 delegates from around the world to present and discuss the latest research on normal physiological
functions and pathological mechanisms of molecular pathways that are relevant to neurodegenerative diseases.
Vassar and Zheng Molecular Neurodegeneration 2014, 9:34 Page 2 of 3
http://www.molecularneurodegeneration.com/content/9/1/34[13-15]. Additionally, innovative studies of mechanisms
of neurotoxicity have revealed roles for micro-RNAs,
transcription factors, and trafficking molecules in AD
[16-20]. Novel therapies based on many of these discov-
eries are also in development, like anti-tau antibodies for
AD and other tauopathies [14].
In summary, this review series aims to encapsulate the
themes discussed at the Third International Conference on
Molecular Neurodegeneration and provide state-of-the-art
knowledge of a wide range of fields in neurodegeneration
research. It is the hope of the editors that the knowledge
conveyed in the review series will provide quality informa-
tion to readers and stimulate further scientific advances in
molecular neurodegeneration that may someday bring an
end to these devastating neurodegenerative disorders.
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